Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T57718
|
||||
| Former ID |
TTDI02217
|
||||
| Target Name |
Melanoma-associated antigenC2
|
||||
| Gene Name |
MAGEC2
|
||||
| Synonyms |
CT10; Cancer/testis antigen 10; Hepatocellular carcinomaassociated antigen 587; MAGEC2 antigen; MAGEE1 antigen; MAGEC2
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Non-small cell lung cancer [ICD10: C33-C34] | ||||
| Function |
Proposed to enhance ubiquitin ligase activity of RING- type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex.
|
||||
| BioChemical Class |
Melanoma associated antigen family
|
||||
| UniProt ID | |||||
| Sequence |
MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSS
LILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQK GEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPV ILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIK GNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFL WGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASE SLSVMSSNVSFSE |
||||
| Drugs and Mode of Action | |||||
| Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
| TEP | EXP Info | ||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.